Barclays’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $317K | Buy |
17,647
+4,851
| +38% | +$67.8K | ﹤0.01% | 3467 |
|
|
2026
Q1 | $121K | Sell |
12,796
-91,768
| -88% | -$1.01M | ﹤0.01% | 3948 |
|
|
2025
Q4 | $1.3M | Buy |
104,564
+10,101
| +11% | +$134K | ﹤0.01% | 3254 |
|
|
2025
Q3 | $1.35M | Sell |
94,463
-73,551
| -44% | -$1.01M | ﹤0.01% | 3182 |
|
|
2025
Q2 | $2.06M | Buy |
168,014
+15,497
| +10% | +$225K | ﹤0.01% | 2823 |
|
|
2025
Q1 | $3.35M | Sell |
152,517
-32,507
| -18% | -$764K | ﹤0.01% | 2233 |
|
|
2024
Q4 | $4.2M | Buy |
185,024
+121
| +0.1% | +$2.64K | ﹤0.01% | 2318 |
|
|
2024
Q3 | $3.36M | Buy |
184,903
+159,736
| +635% | +$3.7M | ﹤0.01% | 2425 |
|
|
2024
Q2 | $733K | Sell |
25,167
-49,076
| -66% | -$1.46M | ﹤0.01% | 2791 |
|
|
2024
Q1 | $2.63M | Buy |
74,243
+8,438
| +13% | +$337K | ﹤0.01% | 2342 |
|
|
2023
Q4 | $2.87M | Buy |
65,805
+24,327
| +59% | +$957K | ﹤0.01% | 2615 |
|
|
2023
Q3 | $1.58M | Sell |
41,478
-13,370
| -24% | -$563K | ﹤0.01% | 2027 |
|
|
2023
Q2 | $2.26M | Buy |
54,848
+20,551
| +60% | +$989K | ﹤0.01% | 1817 |
|
|
2023
Q1 | $1.97M | Sell |
34,297
-73,948
| -68% | -$4.17M | ﹤0.01% | 2213 |
|
|
2022
Q4 | $6.07M | Buy |
108,245
+47,418
| +78% | +$2.41M | ﹤0.01% | 1487 |
|
|
2022
Q3 | $2.58M | Buy |
60,827
+20,139
| +49% | +$1.03M | ﹤0.01% | 1574 |
|
|
2022
Q2 | $2.2M | Buy |
40,688
+11,763
| +41% | +$706K | ﹤0.01% | 1801 |
|
|
2022
Q1 | $1.86M | Buy |
28,925
+9,040
| +45% | +$595K | ﹤0.01% | 1921 |
|
|
2021
Q4 | $1.33M | Sell |
19,885
-25,644
| -56% | -$1.73M | ﹤0.01% | 2636 |
|
|
2021
Q3 | $3.12M | Sell |
45,529
-9,729
| -18% | -$687K | ﹤0.01% | 1984 |
|
|
2021
Q2 | $3.77M | Buy |
55,258
+16,666
| +43% | +$1.18M | ﹤0.01% | 1760 |
|
|
2021
Q1 | $2.67M | Sell |
38,592
-8,235
| -18% | -$558K | ﹤0.01% | 2039 |
|
|
2020
Q4 | $3.04M | Sell |
46,827
-13,850
| -23% | -$745K | ﹤0.01% | 1914 |
|
|
2020
Q3 | $2.87M | Sell |
60,677
-9,596
| -14% | -$456K | ﹤0.01% | 1801 |
|
|
2020
Q2 | $3.3M | Buy |
70,273
+17,722
| +34% | +$871K | ﹤0.01% | 1691 |
|
|
2020
Q1 | $2.35M | Buy |
52,551
+44,796
| +578% | +$2.35M | ﹤0.01% | 2149 |
|
|
2019
Q4 | $451K | Buy |
7,755
+4,406
| +132% | +$262K | ﹤0.01% | 4387 |
|
|
2019
Q3 | $201K | Sell |
3,349
-78,956
| -96% | -$4.7M | ﹤0.01% | 4963 |
|
|
2019
Q2 | $4.6M | Buy |
82,305
+55,896
| +212% | +$2.88M | ﹤0.01% | 1939 |
|
|
2019
Q1 | $1.47M | Sell |
26,409
-16,318
| -38% | -$831K | ﹤0.01% | 2949 |
|
|
2018
Q4 | $1.93M | Buy |
42,727
+13,621
| +47% | +$747K | ﹤0.01% | 2447 |
|
|
2018
Q3 | $1.92M | Sell |
29,106
-64,147
| -69% | -$3.99M | ﹤0.01% | 2928 |
|
|
2018
Q2 | $6.01M | Buy |
93,253
+73,684
| +377% | +$4.56M | 0.01% | 1586 |
|
|
2018
Q1 | $1.08M | Buy |
19,569
+9,476
| +94% | +$497K | ﹤0.01% | 3110 |
|
|
2017
Q4 | $483K | Sell |
10,093
-10,698
| -51% | -$524K | ﹤0.01% | 3866 |
|
|
2017
Q3 | $1.05M | Buy |
20,791
+13,600
| +189% | +$698K | ﹤0.01% | 2951 |
|
|
2017
Q2 | $392K | Buy |
7,191
+3,145
| +78% | +$150K | ﹤0.01% | 3754 |
|
|
2017
Q1 | $170K | Sell |
4,046
-89,018
| -96% | -$3.8M | ﹤0.01% | 4467 |
|
|
2016
Q4 | $3.99M | Buy |
93,064
+47,120
| +103% | +$1.92M | ﹤0.01% | 1555 |
|
|
2016
Q3 | $1.9M | Buy |
45,944
+43,156
| +1,548% | +$1.81M | ﹤0.01% | 2043 |
|
|
2016
Q2 | $111K | Buy |
2,788
+2,714
| +3,668% | +$97.6K | ﹤0.01% | 4334 |
|
|
2016
Q1 | $2K | Buy |
+74
| New | +$2.31K | ﹤0.01% | 5862 |
|
|
2015
Q4 | – | Sell |
-296
| Closed | -$9K | – | 6230 |
|
|
2015
Q3 | $9K | Sell |
296
-900
| -75% | -$28.1K | ﹤0.01% | 5820 |
|
|
2015
Q2 | $32K | Sell |
1,196
-641
| -35% | -$17.1K | ﹤0.01% | 5417 |
|
|
2015
Q1 | $45K | Sell |
1,837
-3,110
| -63% | -$73.5K | ﹤0.01% | 5354 |
|
|
2014
Q4 | $109K | Buy |
4,947
+1,346
| +37% | +$27.3K | ﹤0.01% | 5136 |
|
|
2014
Q3 | $72K | Buy |
3,601
+2,490
| +224% | +$49.6K | ﹤0.01% | 5589 |
|
|
2014
Q2 | $21K | Sell |
1,111
-1,186
| -52% | -$22.1K | ﹤0.01% | 6483 |
|
|
2014
Q1 | $42K | Sell |
2,297
-48,103
| -95% | -$928K | ﹤0.01% | 6134 |
|
|
2013
Q4 | $968K | Buy |
50,400
+6,376
| +14% | +$117K | ﹤0.01% | 3436 |
|
|
2013
Q3 | $720K | Sell |
44,024
-4,671
| -10% | -$75K | ﹤0.01% | 3703 |
|
|
2013
Q2 | $729K | Buy |
+48,695
| New | +$714K | ﹤0.01% | 3767 |
|
Other funds holding IART
RCMNY
PCMI
Barclays's IART Position: Q2 2026 in Review
Barclays increased its Integra LifeSciences (IART) stake by 38% in Q2 2026, buying an estimated $67.8K and bringing the position to 17,647 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #3467.
Barclays first reported a position in IART in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.07M in Q4 2022. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.
- Barclays held 17,647 shares of Integra LifeSciences worth $317K as of Q2 2026.
- Barclays bought 4,851 Integra LifeSciences shares in Q2 2026, an estimated $67.8K.
- Integra LifeSciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3467 holding.
- Barclays first reported a position in Integra LifeSciences in Q2 2013 and has held it in 52 quarters since.
- Barclays's Integra LifeSciences position peaked at $6.07M in Q4 2022.
- 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.